Advances in the diagnosis and management of keratoconjunctivitis sicca

Current Opinion in Ophthalmology

Volumn 9, Issue 4, 1998, Pages 50-53

  Pflugfelder, Stephen C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC TEST; HUMAN; KERATOCONJUNCTIVITIS SICCA; PATHOGENESIS; PRIORITY JOURNAL; WOUND HEALING;

ANIMALS; CORNEA; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL GROWTH FACTOR; GROWTH SUBSTANCES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; OPHTHALMIC SOLUTIONS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 0031695768     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199808000-00009     Document Type: Article

References (37)

1. Pflugfelder SC, Tseng SCG, Sanabria O, Kell H, Garcia C, Felix C, Feuer W, Reis B: Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998, 17:38-56. This article reports that keratoconjunctivitis sicca worsens as aqueous tear production decreases and is greatest in patients with Sjögren's syndrome, an autoimmune condition where the ability to reflex tear in response to sensory stimulation is lost. Compared with other tear film disorders, eyes with keratoconjunctivitis were found to have an irregular corneal surface by the xeroscope.
2. Yoshino K, Monroy D, Pflugfelder SC: Cholinergic stimulation of lactoferrin and epidermal growth factor secretion by the human lacrimal gland. Cornea 1996, 15:617-621.
3. Murillo-Lopez F, Pflugfelder SC: Dry eye. In The Cornea. Edited by Krachmer J, Mannis M, Holland E. St Louis: Mosby; 1996: 663-686. This article reports that epidermal growth factor, EGF, is secreted by the human lacrimal gland in response to neurotransmitters released by cholinergic nerves. This indicates that intact ocular surface-lacrimal gland reflex arcs are essential for delivering tear growth factors to the ocular surface.
4. Sjögren H: Zur kenntnis dur keratoconjunctivitis sicca (keratitis filiformis bei hypofunktion der tranendrusen). Acta Ophthalmol 1933, 2:1-151.
5. Feenstra RP, Tseng SCG: What is actually stained by rose bengal? Arch Ophthalmol 1992, 110:984-993.
6. Pflugfelder SC, Tseng SCG, Yoshino K, Monroy D, Felix C, Reis B: Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. Ophthalmology 1997, 104:223-235. The authors report that there is an inverse correlation between the number of mucus producing conjunctival goblet cells and expression of a high molecular weight differentiation-dependent antigen, MEM2 (mucosal epithelial mucin 2), with the intensity of ocular surface rose bengal staining. This confirms the hypothesis of Feenstra and Tseng (Arch Ophthalmol 1992, 110:984-993.) that a normal mucus coating prevents rose bengal staining of the ocular surface epithelium.
7. Feenstra RP, Tseng SCG: Comparison of rose bengal and fluorescein staining. Ophthalmology 1992, 99:605-617.
8. Gobbels M, Spitznas M: Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992, 99:873-878.
9. Rieger G: Contrast sensitivity in patients with keratoconjunctivitis sicca before and after artificial tear application. Graefes Arch Clin Exp Ophthalmol 1993, 231:577-579.
10. Morkeberg JC, Edmund C, Prause JU, Lanng S, Koch C, Michaelsen KF: Ocular findings in cystic fibrosis patients receiving vitamin A supplementation. Graefes Arch Clin Exp Ophthalmol 1995, 233:709-713.
11. Tseng SCG: Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology 1985, 92:728-733.
12. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC: Sjögren's syndrome: cytokine and Epstein-Barr virus gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci 1994, 35:3493-3504. Reports that the conjunctival epithelium in patients with Sjögren's syndrome keratoconjunctivitis sicca shows aberrant expression of the immune adhesion molecules, HLA class II, and ICAM-1 antigens. Furthermore, these cells contain increased levels of inflammatory cytokines. This paper provides new evidence that there may be an immunological mechanism for keratoconjunctivitis sicca.
13. Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A: Flow cytometry in impression cytology specimens: a new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 1997, 38:1458-1464.
14. Krenzer KL, Freddo TF: Cytokeratin expression in normal human bulbar conjunctiva obtained by impression cytology. Invest Ophthalmol Vis Sci 1997, 38:142-152.
15. Pflugfelder SC, Huang AJW, Feuer W, Chuchovski PT, Pereira I, Tseng SCG: Conjunctival cytologic features of primary Sjögren's syndrome. Ophthalmology 1990, 97:985-991.
16. Raphael M, Bellefgih S, Piette JCh, Le Hoang P, Debre P, Chomette G: Conjunctival biopsy in Sjogren's syndrome: correlations between histologic and immunohistochemical features. Histopathology 1988, 13:191-202.
17. Power WJ, Mullaney P, Farrell M, Collum LM: Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome. Cornea 1993, 12:507-511.
18. Pflugfelder SC, Ji Z, Naqui R: Immune cytokine RNA expression in normal and Sjögren's syndrome conjunctiva. Invest Ophthalmol Vis Sci (ARVO Abstracts) 1996, 37:5358.
19. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB: Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996, 107:778-782.
20. Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW: IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995, 99:148-154.
21. Nagpal S, Thacher SM, Patel S, Friant S, Malhotra M, Shafer J, et al.: Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ 1996, 7:1783-1791.
22. Ortonne JP: Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996, 135(suppl 49):1-5.
23. Ichijima H, Petrol WM, Jester JV, Cavanagh HD: Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992, 11:221-5.
24. Ubels JL, McCartney MD, Lantz WK, Beaird J, Doyalan A, Edelhauser HF: Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol 1995, 113:371-378. Corneal epithelial permeability increases and the normal pattern of differentiation is disrupted by tear solutions containing benzalkonium chloride or EDTA. Compared to untreated eyes, nonpreserved artificial tear solutions containing a bicarbonate buffer were found to have no effect on corneal epithelial permeability, ultrastructure and mucus production.
25. Gilbard JP, Rossi SR, Heyda KG: Ophthalmic solutions, the ocular surface and a unique artificial tear formulation. Am J Ophthalmol 1989, 107:348-355.
26. Nelson JD, Farris RL: Sodium hyaluronate and polyvinyl alcohol artificial tear preparations: a comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol 1988, 106:484-487.
27. Borel JT, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM: In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol 1996, 35:115-246.
28. Kazwan RL, Salisbury MA, Ward DA: Spontaneous canine keratoconjunctivitis sicca: a useful model for human keratoconjunctivitis sicca. Treatment with cyclosporin eye drops. Arch Ophthalmol 1988, 106:484-487.
29. Gunduz K, Ozdemir O: Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome. Acta Ophthalmol 1994, 72:438-442.
30. Lambert RW, Gao J, Kelleher RS, Wickham LA, Sullivan DA: Neural, endocrine and immune regulation of secretory component production by lacrimal gland acinar cells. Adv Exp Med Biol 1995, 371A:221-224. The androgen hormone, dihydrotestosterone (DHT) was found to increase secretory component release by cultured lacrimal gland acinar epithelium following a short (3 hour) exposure. This effect was mediated by binding of DHT to androgen receptors within the cell nucleus, and event that was followed by initiation of transcription of secretory component messenger RNA.
31. Sullivan DA, Block L, Pena JD: Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal gland. Acta Ophthalmol Scand 1996, 74:421-35.
32. Sullivan DA, Edwards JA: Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome. J Steroid Biochem Mol Biol 1997, 60:237-245. A report that lacrimal gland secretory function improves with systemically administered androgen hormone, but not immunosuppressive therapy (corticosteroid, cyclosporine, or cyclophosphamide) in a murine model of Sjögren's syndrome. These findings are consistent with previous reports that androgen hormones decrease lymphocytic infiltration in the lacrimal glands of these mice and also increase release of secretory component from cultured lacrimal gland acinar epithelium.
33. Sullivan DA, Rocha FJ, Sato EH: Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome. Adv Exp Med Biol 1995, 371B:1199-202.
34. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC: Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 1996, 15:605-614. This article reports that the multifunctional cytokine, TGF-β (transforming growth factor-beta), is present in the tear fluid in high concentration. TGF-β has the reported capability to induce epithelial proliferation and suppress inflammation.
35. Nava A, Barton K, Monroy D, Pflugfelder SC: Dynamics of EGF concentrations in tear fluid. Cornea 1997, 16:430-438.
36. Van Setten GB, Viinikka L, Tervo T: Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol 1989, 22:184-187.
37. Van Setten GB, Schultz GS: Transforming growth factor alpha is a constant component of tear fluid. Graefes Arch Clin Exp Ophthalmol 1994, 232:523-526.